Cargando…
Clinical efficacy and safety of astragalus injection combined with ACEI/ARB in the treatment of diabetic kidney disease: Protocol for a systematic review and meta-analysis
Kidney disease is a common complication of diabetes and the main cause of end-stage renal disease. Astragalus (Huangqi) injection in combination with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers (ACEI/ARBs) have been widely used for the treatment of diabetic kidney disease...
Autores principales: | Zhu, Zhiyue, Zhang, Qi, Liu, Le, Bao, Pengjie, Liu, Shilin, Song, Chaoqun, Yang, Wenbo, Nan, Zheng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9750634/ https://www.ncbi.nlm.nih.gov/pubmed/36626537 http://dx.doi.org/10.1097/MD.0000000000031490 |
Ejemplares similares
-
Clinical efficacy and safety of Xuefu Zhuyu decoction in the treatment of diabetic kidney disease: A protocol for systematic review and meta-analysis
por: Song, Chaoqun, et al.
Publicado: (2022) -
Safety of ACEi and ARB in COVID‐19 management: A retrospective analysis
por: Kumar, Sabina, et al.
Publicado: (2022) -
ACEIs and ARBs and Their Correlation with COVID-19: A Review
por: Yehualashet, Awgichew Shewasinad, et al.
Publicado: (2020) -
The role of ACEIs/ARBs in COVID-19: Friend or foe?
por: Zhou, Zhe, et al.
Publicado: (2020) -
Withdrawal of ACEIs or ARBs in hospitalised patients with COVID-19
Publicado: (2021)